Toll-Like Receptor 4, 2, and Interleukin 1 Receptor Associated Kinase4: Possible Diagnostic Biomarkers in Myelodysplastic Syndrome Patients

Myelodysplastic syndrome (MDS) is a clonal hematologic disorder that requires the integration of morphologic, cytogenetic, hematologic, and clinical findings for a successful diagnosis. Trying to find ancillary tests such as biomarkers improve the diagnosis process. Several studies showed that a dis...

Full description

Saved in:
Bibliographic Details
Published in:Advanced biomedical research 2024-01, Vol.13 (1), p.17-17
Main Authors: Khalilian, Parvin, Eskandari, Nahid, Sharifi, Mohammad Jafar, Soltani, Mohammad, Nematollahi, Pardis
Format: Article
Language:English
Subjects:
B cells
Biological markers
Biomarkers
Bone marrow
Cytogenetics
Diagnosis
Diagnostic systems
Ethylenediaminetetraacetic acid
Hematological diseases
Immune system
Innate immunity
Interleukin 1
Interleukins
irak4
Leukemia
Malignancy
Medical research
Medicine, Experimental
Myelodysplastic syndrome
Myelodysplastic syndromes
Neoplasms
Proteins
tlr2
TLR2 protein
tlr4
TLR4 protein
Toll-like receptors
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Myelodysplastic syndrome (MDS) is a clonal hematologic disorder that requires the integration of morphologic, cytogenetic, hematologic, and clinical findings for a successful diagnosis. Trying to find ancillary tests such as biomarkers improve the diagnosis process. Several studies showed that a disordered immune system is associated with MDS. The chronic activated innate immune system, particularly the Toll-like receptors (TLRs) pathway could be involved in the induction of the inflammation. In the present study, we investigated the expression of , and in bone marrow (BM) of MDS patients, the leukemia group, and the healthy group. For this purpose, we assessed the expression of , and by real time-PCR. In line with new findings, we demonstrated that the expression of , and significantly increased in MDS BM compared with the healthy group. Moreover, expression raised significantly in MDS patients compared with other studied hematologic neoplasms. Also, the expression levels of and significantly increased in MDS in comparison to some studied non-MDS malignancies ( ˂ 0.05). Receiver operating characteristics (ROC) analysis and area under the curve (AUC) suggested that the expression of , and (AUC = 0.702, AUC = 0.75, and AUC = 0.682, respectively) had acceptable diagnostic values to identify MDS from the other understudied leukemias. Overall, the expression of , and could be potential biomarkers for discriminating MDS from some hematologic disorders.
ISSN:2277-9175
2277-9175
DOI:10.4103/abr.abr_67_23